These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

652 related articles for article (PubMed ID: 26313372)

  • 1. Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009.
    Dinan MA; Mi X; Reed SD; Lyman GH; Curtis LH
    JAMA Oncol; 2015 Nov; 1(8):1098-109. PubMed ID: 26313372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009.
    Dinan MA; Mi X; Reed SD; Hirsch BR; Lyman GH; Curtis LH
    JAMA Oncol; 2015 May; 1(2):158-66. PubMed ID: 26181015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between physician characteristics and the use of 21-gene recurrence score genomic testing among Medicare beneficiaries with early-stage breast cancer, 2008-2011.
    Wilson LE; Pollack CE; Greiner MA; Dinan MA
    Breast Cancer Res Treat; 2018 Jul; 170(2):361-371. PubMed ID: 29536319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010-2013.
    Parsons BM; Landercasper J; Smith AL; Go RS; Borgert AJ; Dietrich LL
    Breast Cancer Res Treat; 2016 Sep; 159(2):315-26. PubMed ID: 27507245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncotype Dx assay and breast cancer in the United States: usage and concordance with chemotherapy.
    Enewold L; Geiger AM; Zujewski J; Harlan LC
    Breast Cancer Res Treat; 2015 May; 151(1):149-56. PubMed ID: 25859924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of 21-Gene Assay (OncotypeDX) Testing and Receipt of Chemotherapy in the Medicare Breast Cancer Patient Population Following Initial Adoption.
    Dinan MA; Wilson LE; Reed SD; Griggs JJ; Norton EC
    Clin Breast Cancer; 2020 Dec; 20(6):487-494.e1. PubMed ID: 32653473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy Costs and 21-Gene Recurrence Score Genomic Testing Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005 to 2011.
    Dinan MA; Wilson LE; Reed SD
    J Natl Compr Canc Netw; 2019 Mar; 17(3):245-254. PubMed ID: 30865923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
    Partin JF; Mamounas EP
    Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
    J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided?
    Jasem J; Fisher CM; Amini A; Shagisultanova E; Rabinovitch R; Borges VF; Elias A; Kabos P
    J Natl Compr Canc Netw; 2017 Apr; 15(4):494-503. PubMed ID: 28404760
    [No Abstract]   [Full Text] [Related]  

  • 11. Adjuvant Chemotherapy Use and Health Care Costs After Introduction of Genomic Testing in Breast Cancer.
    Epstein AJ; Wong YN; Mitra N; Vachani A; Hin S; Yang L; Smith-McLallen A; Armstrong K; Groeneveld PW
    J Clin Oncol; 2015 Dec; 33(36):4259-67. PubMed ID: 26598749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should women with early breast cancer under 40 years of age have a routine 21-gene recurrence score testing: A SEER database study.
    Liu KH; Zhang L; Chen JX; Lian CL; Wang J; He ZY; Wu SG
    Breast; 2020 Feb; 49():233-241. PubMed ID: 31918322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of 21-gene recurrence score assay and adjuvant chemotherapy use in the medicare population, 2008-2011.
    Su KW; Hall J; Soulos PR; Abu-Khalaf MM; Evans SB; Mougalian SS; Rutter CE; Davidoff AJ; Gross CP
    J Geriatr Oncol; 2016 Jan; 7(1):15-23. PubMed ID: 26704661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.
    Ignatiadis M; Azim HA; Desmedt C; Veys I; Larsimont D; Salgado R; Lyng MB; Viale G; Leyland-Jones B; Giobbie-Hurder A; Kammler R; Dell'Orto P; Rothé F; Laïos I; Ditzel HJ; Regan MM; Piccart M; Michiels S; Sotiriou C
    JAMA Oncol; 2016 Feb; 2(2):217-24. PubMed ID: 26633571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence Scores.
    Chen J; Wu X; Christos PJ; Formenti S; Nagar H
    Breast Cancer Res; 2018 Apr; 20(1):26. PubMed ID: 29661221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario.
    Levine MN; Julian JA; Bedard PL; Eisen A; Trudeau ME; Higgins B; Bordeleau L; Pritchard KI
    J Clin Oncol; 2016 Apr; 34(10):1065-71. PubMed ID: 26598746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis.
    Orucevic A; Heidel RE; Bell JL
    Breast Cancer Res Treat; 2016 Jun; 157(3):427-35. PubMed ID: 27206678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of 70-Gene Signature Assay Findings With Physicians' Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay.
    Tsai M; Lo S; Audeh W; Qamar R; Budway R; Levine E; Whitworth P; Mavromatis B; Zon R; Oldham D; Untch S; Treece T; Blumencranz L; Soliman H
    JAMA Oncol; 2018 Jan; 4(1):e173470. PubMed ID: 29075751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
    Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
    JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile.
    Jasem J; Amini A; Rabinovitch R; Borges VF; Elias A; Fisher CM; Kabos P
    J Clin Oncol; 2016 Jun; 34(17):1995-2002. PubMed ID: 27001563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.